NKT cells: What's in a name?

Nature Reviews Immunology

Volumn 4, Issue 3, 2004, Pages 231-237

  Godfrey, Dale I ^a   MacDonald, H Robson ^b   Kronenberg, Mitchell ^c   Smyth, Mark J ^d   Van Kaer, Luc ^e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^c LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; CLASSIFICATION; HUMAN; HUMAN CELL; IMMUNOREGULATION; LYMPHOCYTE SUBPOPULATION; NATURAL KILLER CELL; NATURAL KILLER CELL SUBPOPULATION; NATURAL KILLER CELL TYPE 1; NATURAL KILLER CELL TYPE 2; NATURAL KILLER LIKE CELL; NOMENCLATURE; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

EID: 1542511203     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1309     Document Type: Review

References (101)

1. + T cell populations. Int. Immunol. 7, 1157-1161 (1995).
2. Budd, R. C. et al. Developmentally regulated expression of T cell receptor β-chain variable domains in immature thymocytes. J. Exp. Med. 166, 577-582 (1987).
3. Fowlkes, B. J. et al. A novel population of T-cell receptor αβ-bearing thymocytes which predominantly expresses a single Vβ-gene family. Nature 329, 251-254 (1987).
4. - mouse thymocytes. Proc. Natl Acad. Sci. USA 64, 8578-8582 (1987).
5. - T cells produce IL-4. J. Immunol. 149, 1211-1215 (1992).
6. + cells. J. Immunol. 145, 3209-3215 (1990).
7. + thymocytes. J. Immunol. 146, 1113-1117 (1991).
8. - thymocytes with specific lymphokine secretion. Eur. J. Immunol. 23, 307-310 (1993).
9. + T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J. Exp. Med. 179, 1285-1295 (1994).
10. + T cells acquire specific lymphokine secretion potentials during thymic maturation. Nature 353, 68-71 (1991).
11. Bendelac, A., Matzinger, P., Seder, R. A., Paul, W. E. & Schwartz, R. H. Activation events during thymic selection. J. Exp. Med. 175, 731-742 (1992).
12. + T cell subsets: a subset (Thy0) that secretes diverse cytokines and overexpresses the Vβ8 T cell receptor gene family. J. Exp. Med. 176, 269-274 (1992).
13. + T cell receptor αβ cells in the liver of mice. J. Exp. Med. 180, 699-704 (1994).
14. - thymocytes by class I molecules expressed by hematopoietic cells. J. Exp. Med. 178, 901-908 (1993).
15. + thymocytes selected by MHC class I molecules. Science 263, 1774-1778 (1994).
16. + T lymphocytes. Science 268, 863-865 (1995). This was the first study to show that NKT cells are restricted to CD1d.
17. - T cells in mice and humans. J. Exp. Med. 180, 1097-1106 (1994). Type I NKT cells express an invariant T-cell receptor (TCR) α-chain, for example, Vα14-Jα281 (now known as Vα14-Jα18) in mice and Vα24-JαQ (now known as Vα24-Jα18) In humans.
18. Imai, K. et al. Sequence and expression of transcripts of the T-cell antigen receptor α-chain gene in a functional, antigen-specific suppressor-T-cell hybridoma. Proc. Natl Acad. Sci. USA 83, 8708-8712 (1986).
19. Koseki, H., Imai, K., Ichikawa, T., Hayata, I. & Taniguchi, M. Predominant use of a particular α-chain in suppressor T cell hybridomas specific for keyhole limpet hemocyanin. Int. Immunol. 1, 557-564 (1989).
20. + T-cell antigen receptor α-chain expanded in unprimed mice. Proc. Natl Acad. Sci. USA 87, 5248-5252 (1990).
21. + T cell development and early IL-4 production in CD1-deficient mice. Immunity 6, 459-467 (1997).
22. Cui, J. et al. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 278, 1623-1626 (1997).
23. Mendiratta, S. K. et al. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity 6, 469-477 (1997).
24. Smiley, S. T., Kaplan, M. H. & Grusby, M. J. Immunoglobulin E production in the absence of interleukin-4-secreting CD1-dependent cells. Science 275, 977-979 (1997).
25. + T cells. Nature 372, 691-694 (1994).
26. Kawano, T. et al. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 278, 1626-1629 (1997). This paper shows that type I NKT cells recognize and are activated by α-galactosylceramide (α-GalCer) associated with CD1d.
27. Elewaut, D. & Kronenberg, M. Molecular biology of NK T cell specificity and development. Semin. Immunol. 12, 561-568 (2000).
28. Godfrey, D. I., Hammond, K. J., Poulton, L. D., Smyth, M. J. & Baxter, A. G. NKT cells: facts, functions and fallacies. Immunol. Today 21, 573-583 (2000).
29. Kronenberg, M. & Gapin, L. The unconventional lifestyle of NKT cells. Nature Rev. Immunol. 2, 557-568 (2002).
30. MacDonald, H. R. Development and selection of NKT cells. Curr. Opin. Immunol. 14, 250-254 (2002).
31. + thymocytes. J. Exp. Med. 180, 395-399 (1994).
32. + T cells by non-major histocompatibility complex-encoded class I-like molecules expressed on bone marrow derived cells. Proc. Natl Acad. Sci. USA 92, 1200-1204 (1995).
33. + cells. J. Immunol. 164, 2412-2418 (2000).
34. + T cells by CD1-expressing cortical thymocytes. J. Exp. Med. 182, 2091-2096 (1995).
35. - T cells. J. Exp. Med. 180, 1171-1176 (1994).
36. - αβ T cells demonstrates preferential use of several Vβ genes and an invariant TCR α-chain. J. Exp. Med. 178, 1-16 (1993).
37. Kashiwase, K. et al. The CD1d natural killer T-cell antigen presentation pathway is highly conserved between humans and rhesus macaques. Immunogenetics 54, 776-781 (2003).
38. Motsinger, A. et al. Identification and simian immunodeficiency virus infection of CD1d-restricted macaque natural killer T cells. J. Virol. 77, 8153-8158 (2003).
39. Matsuura, A. et al. NKT cells in the rat: organ-specific distribution of NKT cells expressing distinct Vα14 chains. J. Immunol. 164, 3140-3148 (2000).
40. +-like thymocytes in the NOD mouse. Eur. J. Immunol. 26, 2989-2998 (1996).
41. +) T cells that exprese αβ T cell receptors in transporters associated with antigen presentation-1 null and thymus leukemia antigen positive mice. J. Exp. Med. 184, 1579-1584 (1996).
42. Bix, M. & Locksley, R. M. Natural T cells - cells that co-express NKRP-1 and TCR. J. Immunol. 155, 1020-1022 (1995).
43. + cells. Immunol. Lett. 54, 5-9 (1996).
44. Naumov, Y. N. et al. Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Proc. Natl Acad. Sci. USA 98, 13838-13843 (2001).
45. Smyth, M. J., Crowe, N. Y., Takeda, K., Yagita, H. & Godfrey, D. I. NKT cells - conductors of tumor immunity? Curr. Opin. Immunol. 14, 165-171 (2002).
46. + T cells are not CD1d or Vα14-Jα18 dependent.
47. Hammond, K. J. et al. CD1d-restricted NKT cells: an interstrain comparison. J. Immunol. 167, 1164-1173 (2001).
48. Eberl, G. et al. Tissue-specific segregation of CD1d-dependent and CD1d-independent NK T cells. J. Immunol. 162, 6410-6419 (1999).
49. - NKT cells in C57BL/6 mice.
50. Terabe, M. et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nature Immunol. 1, 515-520 (2000).
51. Gumperz, J. E., Miyake, S., Yamamura, T. & Brenner, M. B. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med. 195, 625-636 (2002).
52. + T lymphocytes. J. Immunol. 168, 5514-5520 (2002).
53. + NK T cells activated by α -galactosylceramide-pulsed monocyte-derived dendritic cells. J. Immunol. 168, 3140-3144 (2002).
54. Shao, H., Van Kaer, L., Sun, S. L., Kaplan, H. J. & Sun, D. Infiltration of the inflamed eye by NKT cells in a rat model of experimental autoimmune uveitis. J. Autoimmun. 21, 37-45 (2003).
55. Lee, P. T., Benlagha, K., Teyton, L. & Bendelac, A. Distinct functional lineages of human Vα24 natural killer T cells. J. Exp. Med. 195, 637-641 (2002).
56. Benlagha, K., Weiss, A., Beavis, A., Teyton, L. & Bendelac, A. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers. J. Exp. Med. 191, 1895-1903 (2000).
57. + T cells. J. Immunol. 162, 7067-7074 (1999). The authors describe that some CD1d-dependent Vα14-Jα18 NKT cells do not express the NK1.1 marker.
58. Hameg, A. et al. A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the α-galactosylceramide antigen. J. Immunol. 165, 4917-4926 (2000).
59. + CD1d-dependent precursor stage. J. Exp. Med. 195, 835-844 (2002).
60. Benlagha, K., Kyin, T., Beavis, A., Teyton, L. & Bendelac, A. A thymic precursor to the NKT cell lineage. Science 296, 553-555 (2002).
61. - stage (references 59 and 60 only).
62. + T cells lose NK1.1 expression upon in vitro activation. J. Immunol. 158, 5112-5119 (1997).
63. Eberl, G. & Macdonald, H. R. Rapid death and regeneration of NKT cells in anti-CD3-ε- or IL-12-treated mice - a major role for bone marrow in NKT cell homeostasis. Immunity 9, 345-353 (1998).
64. Eberl, G. & MacDonald, H. R. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur. J. Immunol. 30, 985-992 (2000).
65. Leite-de-Moraes, M. C. et al. Fas/Fas ligand interactions promote activation-induced cell death of NK T lymphocytes. J. Immunol. 165, 4367-4371 (2000).
66. Nakagawa, R. et al. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by α-galactosylceramide in mice. J. Immunol. 166, 6578-6584 (2001).
67. Osman, Y. et al. Activation of hepatic NKT cells and subsequent liver injury following administration of α-galactosylceramide. Eur. J. Immunol. 30, 1919-1928 (2000).
68. Hayakawa, Y. et al. Critical contribution of IFN-γ and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of α-galactosylceramide. Eur. J. Immunol. 31, 1720-1727 (2001).
69. Crowe, N. Y. et al. Glycolipid antigen drives rapid expansion and sustained cytokine production by NKT cells. J. Immunol. 171, 4020-4027 (2003).
70. Wilson, M. T. et al. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc. Natl Acad. Sci. USA 100, 10913-10918 (2003). Following stimulation in vivo, references 69 and 70 show that most NKT cells do not die within hours due to activation-induced cell death (as previously thought). Instead, they downregulate NK1.1 expression and undergo marked but transient clonal expansion to ten times their steady-state levels. HK1.1 expression remains reduced on antigen-experienced NKT cells for at least 12 days.
71. Park, S. H., Kyin, T., Bendelac, A. & Carnaud, C. The contribution of NKT cells, NK cells, and other γ-chain-dependent non-T non-B cells to IL-12-mediated rejection of tumors. J. Immunol. 170, 1197-1201 (2003).
72. Lizuka, K., Naidenko, O. V., Plougastel, B. F., Fremont, D. H. & Yokoyama, W. M. Genetically linked C-type lectin-related ligands for the NKRP1 family of natural killer cell receptors. Nature Immunol. 4, 801-807 (2003).
73. Behar, S. M., Podrebarac, T. A., Roy, C. J., Wang, C. R. & Brenner, M. B. Diverse TCRs recognize murine CD1. J. Immunol. 162, 161-167 (1999).
74. Chiu, Y. H. et al. Distinct subsets of CD1d-restricted T cells recognize self-antigens loaded in different cellular compartments. J. Exp. Med. 189, 103-110 (1999).
75. +.
76. Park, S. H. et al. The mouse CD1d-restricted repertoire is dominated by a few autoreactive T cell receptor families. J. Exp. Med. 193, 893-904 (2001).
77. + T cells with a transgenic variant TCR. J. Immunol. 165, 168-174 (2000).
78. Huber, S., Sartini, D. & Exley, M. Role of CD1d in coxsackievirus B3-induced myocarditis. J. Immunol. 170, 3147-3153 (2003).
79. Ghiu, Y. H. et al. Multiple defects in antigen presentation and T cell development by mice expressing cytoplasmic tail-truncated CD1d. Nature Immunol. 3, 55-60 (2002).
80. Baron, J. L. et al. Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection. Immunity 16, 583-594 (2002).
81. H2-like CD1d-reactive T cells that can suppress mixed lymphocyte responses. J. Immunol. 167, 5531-5534 (2001).
82. Heiken, H., Schulz, R. J., Ravetch, J. V., Reinherz, E. L. & Koyasu, S. T lymphocyte development in the absence of Fc-ε receptor I-γ subunit - analysis of thymic-dependent and independent αβ and γδ pathways. Eur. J. Immunol. 26, 1935-1943 (1996).
83. + T cells upon antigen expression in the thymus or in the liver. Eur. J. Immunol. 29, 2330-2343 (1999).
84. d. Proc. Natl Acad. Sci. USA 95, 8199-8204 (1998).
85. + T cells. J. Immunol. 154, 2009-2015 (2000).
86. Treiner, E. et al. Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1. Nature 422, 164-169 (2003).
87. Shimamura, M. & Huang, Y. Y. Presence of a novel subset of NKT cells bearing an invariant Vα19.1-Jα26 TCR α-chain. FEBS Letters 516, 97-100 (2002).
88. + T cells. Int. Immunol. 10, 1491-1499 (1998).
89. + cells responsible for acute marrow graft rejection are present in thymus-deficient mice. J. Immunol. 149, 403-412 (1992).
90. + NKT cell subsets with distinct cytokine-producing capacity. Blood 100, 11-16 (2002).
91. H1-type inflammatory homing cells. J. Immunol. 171, 2571-2580 (2003).
92. + NKT cells in germ-free mice. Eur. J. Immunol. 30, 620-625 (2000).
93. + NKT cells. Eur. J. Immunol. 31, 2901-2909 (2001).
94. Carding, S. R. & Egan, P. J. γδ T cells: functional plasticity and heterogeneity. Nature Rev. Immunol. 2, 336-345 (2002).
95. + T cell development in CD3-ζ-deficient mice. J. Exp. Med. 182, 891-895 (1995).
96. + thymocytes. Eur. J. Immunol. 28, 1424-1429 (1996).
97. Schumann, J., Voyle, R. B., Wei, B. Y. & MacDonald, H. R. Cutting edge: influence of the TCR Vβ domain on the avidity of CD1d-α -galactosylceramide binding by invariant Vα14 NKT cells. J. Immunol. 170, 5815-5819 (2003).
98. Exley, M.A. et al. CD1d-reactive T-cell activation leads to amelioration of disease caused by diabetogenic encephalomyocarditis virus. J. Leukoc. Biol. 69, 713-718 (2001).
99. Dao, T. et al. Involvement of CD1 in peripheral deletion of T lymphocytes is independent of NK T cells. J. Immunol. 166, 3090-3097 (2001).
100. Gapin, L., Matsuda, J. L., Surh, C. D. & Kronenberg, M. NKT cells derive from double-positive thymocytes that are positively selected by CD1d. Nature Immunol. 2, 971-978 (2001).
101. Hayakawa, Y., Godfrey, D. I. & Smyth, M. J. α -Galactosylceramide: potential immunomodulatory activity and future application. Curr. Med. Chem. 11, 241-252 (2004).